JP7399382B2 - 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤 - Google Patents

組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤 Download PDF

Info

Publication number
JP7399382B2
JP7399382B2 JP2021503531A JP2021503531A JP7399382B2 JP 7399382 B2 JP7399382 B2 JP 7399382B2 JP 2021503531 A JP2021503531 A JP 2021503531A JP 2021503531 A JP2021503531 A JP 2021503531A JP 7399382 B2 JP7399382 B2 JP 7399382B2
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
rhpth
formulation according
samples
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021503531A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020028011A5 (https=
JP2021532110A5 (https=
JP2021532110A (ja
Inventor
ディクシット，ニティン
グェン，ヴィン
スイヤック，ピエール
バス，スチット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2021532110A publication Critical patent/JP2021532110A/ja
Publication of JPWO2020028011A5 publication Critical patent/JPWO2020028011A5/ja
Publication of JP2021532110A5 publication Critical patent/JP2021532110A5/ja
Priority to JP2023194827A priority Critical patent/JP7738046B2/ja
Application granted granted Critical
Publication of JP7399382B2 publication Critical patent/JP7399382B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021503531A 2018-07-30 2019-07-12 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤 Active JP7399382B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023194827A JP7738046B2 (ja) 2018-07-30 2023-11-16 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862711767P 2018-07-30 2018-07-30
US62/711,767 2018-07-30
PCT/US2019/041609 WO2020028011A1 (en) 2018-07-30 2019-07-12 Formulations for improved stability of recombinant human parathyroid hormone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023194827A Division JP7738046B2 (ja) 2018-07-30 2023-11-16 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤

Publications (4)

Publication Number Publication Date
JP2021532110A JP2021532110A (ja) 2021-11-25
JPWO2020028011A5 JPWO2020028011A5 (https=) 2022-07-21
JP2021532110A5 JP2021532110A5 (https=) 2022-07-21
JP7399382B2 true JP7399382B2 (ja) 2023-12-18

Family

ID=69232628

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021503531A Active JP7399382B2 (ja) 2018-07-30 2019-07-12 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤
JP2023194827A Active JP7738046B2 (ja) 2018-07-30 2023-11-16 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023194827A Active JP7738046B2 (ja) 2018-07-30 2023-11-16 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤

Country Status (9)

Country Link
US (1) US20210315978A1 (https=)
EP (1) EP3829625A4 (https=)
JP (2) JP7399382B2 (https=)
KR (1) KR20210038618A (https=)
CN (1) CN112638407A (https=)
AU (1) AU2019315807B2 (https=)
CA (1) CA3107105A1 (https=)
TW (1) TWI831813B (https=)
WO (1) WO2020028011A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102885113B1 (ko) 2018-10-18 2025-11-13 머크 샤프 앤드 돔 엘엘씨 항-rsv 항체의 제제 및 그의 사용 방법
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
US20230190880A1 (en) * 2020-03-30 2023-06-22 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of Human Parathyroid Hormone (PTH) and Methods for Producing Same
WO2025032376A1 (en) * 2023-08-04 2025-02-13 Precise Biopharma Pvt Ltd A room temperature stable solution for injection of abaloparatide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053106A1 (en) 2007-10-26 2009-04-30 Nycomed Danmark Aps Parathyroid hormone formulations and uses thereof
JP2015504087A (ja) 2012-01-20 2015-02-05 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ 安定化ｐｔｈ製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
EP1030658A1 (en) 1997-10-14 2000-08-30 Eli Lilly And Company Method of building and maintaining bone
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
CN100553674C (zh) * 2007-02-02 2009-10-28 重庆科润生物医药研发有限公司 一种重组人甲状旁腺激素(1-84)药物组合物及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053106A1 (en) 2007-10-26 2009-04-30 Nycomed Danmark Aps Parathyroid hormone formulations and uses thereof
JP2015504087A (ja) 2012-01-20 2015-02-05 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ 安定化ｐｔｈ製剤

Also Published As

Publication number Publication date
EP3829625A1 (en) 2021-06-09
WO2020028011A1 (en) 2020-02-06
TW202019461A (zh) 2020-06-01
TWI831813B (zh) 2024-02-11
JP2024003211A (ja) 2024-01-11
KR20210038618A (ko) 2021-04-07
AU2019315807B2 (en) 2025-07-10
US20210315978A1 (en) 2021-10-14
EP3829625A4 (en) 2022-08-10
CA3107105A1 (en) 2020-02-06
JP7738046B2 (ja) 2025-09-11
AU2019315807A1 (en) 2021-02-18
CN112638407A (zh) 2021-04-09
JP2021532110A (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
JP7738046B2 (ja) 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤
CN107920992B (zh) 速效胰岛素组合物
CA2780554C (en) Formulation for hgh and rhigf-1 combination
JP2018162295A (ja) 医薬製剤
CN106456717A (zh) 速效胰岛素组合物
TWI635874B (zh) 艾妥鈣塞(etelcalcetide)(amg 416)之穩定液體調配物
EP3423042B1 (en) A lyophilised pharmaceutical formulation and its use
JP4991522B2 (ja) 成長ホルモン液剤
JP4949828B2 (ja) 溶液中での成長ホルモンの安定化
AU2013368990B2 (en) Pharmaceutical composition
HK40050341A (en) Formulations for improved stability of recombinant human parathyroid hormone
AU2020299978A1 (en) Pharmaceutical compositions for glucagon and GLP-1 co-agonist peptides
CN118555953A (zh) Hgh融合蛋白的高浓度给药剂型
WO2025149039A1 (zh) 长效glp-1/gip双激动剂的药物组合物
HK40111706A (zh) Hgh融合蛋白的高浓度给药剂型

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220712

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20230322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230519

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231018

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20231023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231116

R150 Certificate of patent or registration of utility model

Ref document number: 7399382

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150